BCRXBCRXHealthcare · Drug Manufacturers - Specialty & Generic

BCRX Stock Forecast: BioCryst Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$7.30
−2.67% on the day

The 11 Wall Street analysts covering BioCryst Pharmaceuticals, Inc. hold a median 12-month price target of $17 — +132.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 17 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.9B
Ticker Nerd rank
82/ 100
Median analyst target
$17
Analysts covering
11
Revenue$218.3M+33.6% y/y
Operating income$98.5M
Net income$78.4M
Free cash flow$104.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.6%
1M
−6.3%
YTD
−6.4%
1Y
+4.3%
From 52W high
−34.3%
From 52W low
+17.0%
$6
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BCRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioCryst Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
82/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
95
Volatility
94
Accruals
87
Growth
73
Quality
73
Revisions
65
Momentum
62
Size
35
Issuance
9

Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BCRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BCRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26BCRXHigh $32Median $17Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
9 Buy2 Hold0 Sell
Low $11Median $17High $32

The green dot is the last close — the median target sits +132.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
5 Nov 2026WedbushMaintainsOutperform$18 → $17
30 Sept 2026JP MorganMaintainsNeutral$12 → $13
30 Sept 2026JP MorganMaintainsNeutral—
10 Sept 2026RBC CapitalDowngradeSector Perform$13 → $11
10 Sept 2026RBC CapitalDowngradeSector Perform—
8 Sept 2026NeedhamReiteratesBuy—
8 Sept 2026NeedhamReiteratesBuy$16
6 Aug 2026RBC CapitalMaintainsOutperform$14 → $13
6 Aug 2026RBC CapitalMaintainsOutperform—
6 Aug 2026WedbushMaintainsOutperform—
6 Aug 2026WedbushMaintainsOutperform$21 → $20
13 July 2026JP MorganReinstatesNeutral$12
7 July 2026RBC CapitalMaintainsOutperform$13 → $14
7 July 2026RBC CapitalMaintainsOutperform—
30 June 2026Cantor FitzgeraldMaintainsOverweight—
30 June 2026HC Wainwright & Co.MaintainsBuy—
7 May 2026CitizensMaintainsMarket Outperform—
7 May 2026WedbushMaintainsOutperform—
6 May 2026NeedhamMaintainsBuy—
30 Jan 2026RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BCRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BCRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, BioCryst Pharmaceuticals, Inc. returned +4.3% against +12.2% for the S&P 500, dividends included.

BCRX vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Jan 26Apr 26Jul 26Oct 26BCRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BCRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+16.1%
Analysts raising
1
Analysts cutting
1
Fundamentals

BioCryst Pharmaceuticals, Inc. (BCRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.0×

Cheaper than 63% of US stocks

Price / sales
2.0×

Cheaper than 49% of US stocks

Price / book
−4.2×

Cheaper than 97% of US stocks

EV / EBITDA
5.0×

Cheaper than 53% of US stocks

Growth & margins
Revenue growth (YoY)
13.1%

Higher than 60% of US stocks

Earnings growth (YoY)
193.9%

Higher than 90% of US stocks

Gross margin
98.2%

Higher than 99% of US stocks

Operating margin
48.8%

Higher than 97% of US stocks

Net margin
−37.4%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−221.4%

Higher than 6% of US stocks

Return on assets
56.5%

Higher than 99% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BioCryst Pharmaceuticals, Inc. (BCRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioCryst Pharmaceuticals, Inc. has a market value of $1.9B and an enterprise value of $2.4B.

  • Revenue in the twelve months to 30 June 2026: $940.6M. The latest quarter grew 13.1% year on year.

  • Net income over the same four quarters: −$384.7M, a −40.9% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.50.

  • Free cash flow in the twelve months to 30 June 2026: $373.4M.

  • Shares outstanding: 255.3M.

  • Trailing P/E: 7.0×; forward P/E: 8.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • BioCryst Pharmaceuticals, Inc. employs 435 people — $2.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

BCRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
BCRXBioCryst Pharmaceuticals, Inc.$1.9B82
ETONEton Pharmaceuticals, Inc.$1.8B99
TRLVTrulieve Cannabis Corp.$1.9B71
PRGOPerrigo Co. Plc$2.2B90
ANIPANI Pharmaceuticals, Inc.$1.6B98
ALVOAlvotech$1.6B32
RGCRegencell Bioscience Holdings Ltd.$2.3B22

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioCryst Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BCRX news & analysis

BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting

GlobeNewsWire · 13 Nov 2026positive

BioCryst presented two real-world studies at the ACAAI 2026 Annual Scientific Meeting reporting reduced healthcare resource use among HAE patients who initiated ORLADEYO or switched to it from another prophylactic therapy. The reported reductions included angioedema-related medical visits.

Why it matters — The findings provide real-world evidence about healthcare resource utilization associated with ORLADEYO, BioCryst’s HAE prophylactic therapy.

4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth

Zacks Investment Research · 10 Nov 2026positive

Zacks Investment Research reports that BCRX and three other commercial-stage biotech companies are expanding product sales through rising demand, broader patient access and new market opportunities.

Why it matters — The item groups BCRX among companies experiencing product-sales expansion, a development relevant to tracking its commercial performance.

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call Transcript

Seeking Alpha · 4 Nov 2026neutral

BioCryst Pharmaceuticals held its Q3 2026 earnings call on November 4, 2026. The excerpt lists company executives and participating analysts but provides no discussion of results or business updates.

Why it matters — The call is a source of quarterly information for BCRX watchers, though this excerpt contains no details about the company’s performance or outlook.

BioCryst: Solid Q3 Earnings, But Long-Acting HAE Data Due 2027 The Key Catalyst

Seeking Alpha · 4 Nov 2026positive

BioCryst reported Q3 2026 results ahead of expectations, maintained its 2026 guidance, and noted continued Orladeyo growth. Management highlighted pipeline execution, particularly navenibart, alongside its external-innovation focus and 2030 revenue goal.

Why it matters — BCRX watchers will be following the timing and progress of navenibart data, expected in 2027, as a key pipeline milestone.

BioCryst Pharmaceuticals Q3 Earnings Call Highlights

MarketBeat · 4 Nov 2026positive

BioCryst reported third-quarter growth in ORLADEYO revenue, higher profitability and progress across its HAE portfolio. The company maintained its full-year ORLADEYO revenue outlook following a specialty-pharmacy transition.

Why it matters — The results highlight performance in BioCryst’s HAE portfolio and its continued full-year ORLADEYO revenue outlook.

FAQ

Frequently asked questions about BCRX stock

What is the BCRX stock price forecast for 2026-2027?

The 11 Wall Street analysts covering BioCryst Pharmaceuticals, Inc. have a median 12-month price target of $17, with estimates ranging from $11 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BCRX stock a buy right now?

Of the 11 analysts covering BioCryst Pharmaceuticals, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioCryst Pharmaceuticals, Inc. 82 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BCRX?

As at 17 Nov 2026, BioCryst Pharmaceuticals, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).

Will BCRX stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +132.9% from the last close, and Ticker Nerd's factor model ranks BioCryst Pharmaceuticals, Inc. 82 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BCRX stock forecast for 2030?

No analyst covering BioCryst Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $32 over the next 12 months.

How has BCRX stock performed over the past year?

BioCryst Pharmaceuticals, Inc. returned +4.3% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioCryst Pharmaceuticals, Inc. do?

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for rare diseases, with a primary emphasis on hereditary angioedema (HAE).

What is the latest news on BCRX?

The most recent item we track (GlobeNewsWire, 13 Nov 2026): "BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting". BioCryst presented two real-world studies at the ACAAI 2026 Annual Scientific Meeting reporting reduced healthcare resource use among HAE patients who initiated ORLADEYO or switched to it from another prophylactic therapy. The reported reductions included angioedema-related medical visits.

Company

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for rare diseases, with a primary emphasis on hereditary angioedema (HAE). Its commercial portfolio is centered on ORLADEYO, an oral therapy used to help prevent HAE attacks, alongside RAPIVAB, an injectable antiviral medicine used in the treatment of influenza in the United States. The company also supports a broader rare-disease pipeline built around oral small-molecule and protein-based therapeutics designed to address difficult-to-treat conditions. BioCryst Pharmaceuticals serves patients, physicians, and healthcare systems through specialty pharmaceutical products aimed at chronic disease management and acute treatment needs. Headquartered in Durham, North Carolina, BioCryst Pharmaceuticals plays a focused role in the rare-disease market by combining commercial medicines with targeted drug development expertise.

CEO Mr. Charles K. Gayer · 435 employees · United States · https://www.biocryst.com